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W. Sean Davidson, David D’Alessio, Randy J. Seeley, Patrick Tso,
and Stephen C. Woods. Apolipoprotein A-IV interacts synergisti-
cally with melanocortins to reduce food intake. Am J Physiol Regul
Integr Comp Physiol 290: R202–R207, 2006. First published Septem-
ber 15, 2005; doi:10.1152/ajpregu.00502.2005.—Apolipoprotein (apo)
A-IV is an anorexigenic gastrointestinal peptide that is also synthe-
sized in the hypothalamus. The goal of these experiments was to
determine whether apo A-IV interacts with the central melanocortin
(MC) system in the control of feeding. The third ventricular (i3vt)
administration of a subthreshold dose of apo A-IV (0.5 g) potenti-
ated i3vt MC-induced (metallothionein-II, 0.03 nmol) suppression of
30-min feeding in Long-Evans rats. A subthreshold dose of the MC
antagonist (SHU9119, 0.1 nmol, i3vt) completely attenuated the
anorectic effect of i3vt apo A-IV (1.5 g). The i3vt apo A-IV
significantly elevated the expression of c-Fos in neurons of the
paraventricular nucleus of the hypothalamus, but not in the arcuate
nucleus or median eminence. In addition, c-Fos expression was not
colocalized with proopiomelanocortin-positive neurons. These data
support a synergistic interaction between apo A-IV and melanocortins
that reduces food intake by acting downstream of the arcuate.
melanocortin system; hypothalamus; proopiomelanocortin; c-Fos
FIRST DESCRIBED IN 1977 (31), apolipoprotein (apo) A-IV is a
circulating glycoprotein secreted by the small intestine in
humans (11). In rodents, although apo A-IV is secreted in small
amounts from the liver, the small intestine is the major organ
responsible for its presence in the circulation (1). In the
intestine, apo A-IV is secreted in association with chylomi-
crons during the absorption of lipids, and it is displaced rapidly
from the chylomicrons during their metabolism in the circula-
tion (27, 35). Hence, apo A-IV has been considered a key
peptide involved in the processing of ingested fat by the body.
A possible signaling role of apo A-IV was suggested when it
was found that systemic administration of exogenous apo A-IV
dose dependently decreases food intake of rats (10) and that
administration of apo A-IV antiserum increases food intake
and body weight (9).
Apo A-IV is present in the cerebrospinal fluid, and its
cerebrospinal levels increase when fat is absorbed (10). More-
over, the third ventricular (i3vt) administration of exogenous
apo A-IV reduces food intake (9). Hence, one site of action of
the anorexic effect of apo A-IV appears to be within the brain.
Consistent with this, apo A-IV is synthesized in the ventrobasal
hypothalamus (17, 18) in the general area in which other
important feeding-related neuropeptides are produced (7, 28,
36), and hypothalamic apo A-IV mRNA levels fluctuate with
metabolic state (20, 22) as well as time of day (21). All of these
findings suggest that apo A-IV likely interacts with other
signals involved in the regulation of energy homeostasis (see
reviews in Refs. 33, 34).
The hypothalamic melanocortin system is important in the
regulation of food intake and body weight (2, 5, 8, 16, 30).
-Melanocyte-stimulating hormone (-MSH) derived from
proopiomelanocortin (POMC) neurons in the hypothalamic
arcuate nucleus (ARC) is the primary agonist for melanocortin
type 3 and 4 receptors (MC3/4-R) in the brain. -MSH is
thought to exert a tonic inhibitory influence over feeding (5,
26). Agouti-related protein is a peptide produced in non-
POMC cells in the ARC and antagonizes MC3/4-R (5, 23).
Consistent with this, agouti-related protein elicits hyperphagia
when it is centrally administered (6, 12, 13). The i3vt admin-
istration of metallothionein-II (MT-II), a synthetic MC3/4-R
agonist, potently reduces feeding (8, 32), whereas i3vt admin-
istration of SHU9119, a synthetic MC3/4-R antagonist, blocks
the anorectic effect of MT-II (30) and elicits feeding when
administered alone at higher doses (12, 13).
The present series of experiments assessed the hypothesis
that central apo A-IV reduces food intake by potentiating the
anorectic effect of central melanocortin agonists. To evaluate
this possibility, a subthreshold dose of apo A-IV that had no
effect on feeding when administered alone was first estab-
lished. This subthreshold dose was then administered concom-
itantly with MT-II, and feeding and body weight were subse-
quently monitored. In complementary experiments, a similar
paradigm was used to establish a subthreshold dose of centrally
administered SHU9119, and this dose was then administered
concomitantly with apo A-IV. Finally, c-Fos expression in the
hypothalamus of rats pretreated with an anorectic dose of apo
A-IV was assessed by using dual-labeled immunohistochem-
istry.
METHODS
Subjects. Male Long-Evans rats (Harlan, Indianapolis, IN), weigh-
ing 340–400 g at the onset of the experiments, were housed in
individual tub cages and maintained in an American Association for
Accreditation of Laboratory Animal Care-accredited room illumi-
nated from 0100 to 1300. All rats were individually handled for 5 min
over 4 successive days to equilibrate their arousal levels before an
experiment. Animals were anesthetized with ketamine/xylazine anes-
thesia (ketamine: 33 mg/rat, xylazine: 4.3 mg/rat; ip) and implanted
with a cannula aimed at the i3vt. Coordinates were on the midline, 2.2
mm posterior to bregma, and 7.5 mm ventral to dura, as previously
described (25). The guide cannula was cemented to anchor screws
Address for reprint requests and other correspondence: S. C. Woods, Dept.
of Psychiatry, Univ. of Cincinnati, 2170 East Galbraith Road, Cincinnati, OH
45237 (e-mail: steve.woods@psychiatry.uc.edu).
The costs of publication of this article were defrayed in part by the payment
of page charges. The article must therefore be hereby marked “advertisement”
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Am J Physiol Regul Integr Comp Physiol 290: R202–R207, 2006.
First published September 15, 2005; doi:10.1152/ajpregu.00502.2005.
0363-6119/06 $8.00 Copyright © 2006 the American Physiological Society http://www.ajpregu.orgR202
 on S
eptem






attached to the skull. After a 10-day recovery period during which
body weight had returned to baseline, placement of the cannula was
confirmed by i3vt infusion of 10 ng of angiotensin II (AT-II) in saline
while the animals were water replete. Only animals drinking in excess
of 5 ml over 1 h after AT-II infusion were included in the study. This
protocol was approved by the University of Cincinnati Institutional
Animal Care and Use Committee.
Reagents. Recombinant rat apo A-IV was expressed in Escherichia
coli and purified in a bioactive form, as described by Liu et al. (19).
Briefly, the protein was expressed in the pET expression system with
an NH2-terminal histidine tag sequence. The protein was isolated from
a sonicated cell extract by passage down a nickel-chelating column.
The His tag was removed by using the Igase protease, which cleaved
a sequence engineered immediately at the NH2-terminus of the mature
protein (24). The mature protein was purified away from the cleaved
tag by a second passage down the chelating column. The recombinant
form of apoA-IV has been shown to be of similar molecular mass and
formed similarly sized reconstituted lipoprotein particles as apo A-IV
isolated from plasma. Most importantly, recombinant apo A-IV was
demonstrated to be as functional as the native form with regard to
suppression of food intake and did not induce a conditioned taste
aversion (19). MT-II and SHU9119 were purchased from Phoenix
Pharmaceuticals. All peptides were dissolved in physiological saline.
Procedures. One week following the AT-II tests, the animals were
adapted to a regimen on which food was removed for the last 4 h of
the light period each day (i.e., from 0900 to 1300). Rats were divided
into four groups (n  10 per group) matched on the basis of 4-h food
intake for the previous 3 days. The same rats were used in experiments
1–5, with 7–10 days of nontesting occurring between experiments.
For each subsequent experiment, the rats were reassigned to novel
groups matched by baseline food intake. There was slight attrition
over the course of the experiments as cannulas malfunctioned.
Experiment 1: Determination of a subthreshold dose of apo A-IV
on food intake and body weight. On the experimental day, the animals
were administered an i3vt bolus injection of saline or 0.5, 1.0, or 1.5
g of apo A-IV at 1100. The injection, therefore, occurred 2 h before
food was returned, as preliminary experiments on other rats indicated
that the variance of food intake following apo A-IV was considerably
reduced after the 2-h delay. All injections were in a volume of 1 l.
Food was then returned, and intake was measured after 30 and 60 min
and 24 h. Body weight was recorded after 24 h. Water was available
at all times.
Experiment 2: Effect of a subthreshold dose of apo A-IV on
MT-II-elicited suppression of food intake and body weight. Rats were
administered two injections on the test day. The injections contained
either saline  saline, apo A-IV (0.5 g)  saline, MT-II (0.03
nmol)  saline, or apo A-IV (0.5 g)  MT-II (0.03 nmol). This dose
of apo A-IV had no effect on food intake or body weight of rats in
experiment 1. The dose of MT-II elicits a reliable decrease in food
intake in our laboratory (30). The first i3vt injection contained either
saline or apo A-IV and occurred at 1100 and was followed 10 min
later by the second i3vt injection that contained either saline or MT-II.
Food intake and body weight were recorded as in experiment 1.
Experiment 3: Effect of apo A-IV on food intake and body weight
when infused 10 min before a subthreshold dose of MT-II. Groups of
rats (n  9 per group) were administered either saline  saline, apo
A-IV (0.5 g)  saline, saline  MT-II (0.01 nmol), or apo A-IV (0.5
g)  MT-II (0.01 nmol) using the same protocol as in experiment 2.
Experiment 4: Determination of a subthreshold dose of SHU9119
on food intake and body weight. Four groups of rats were i3vt
administered either saline or 0.05, 0.1, or 0.2 nmol of SHU9119 at
1100. Procedures were as in experiment 1.
Experiment 5: Effect of SHU9119 on apo A-IV-elicited suppression
of food intake and body weight. Four groups of rats (n  8 per group)
were administered either saline  saline or saline  apo A-IV (1.5
g), SHU9119 (0.1 nmol)  saline, or SHU9119 (0.1 nmol)  apo
A-IV (1.5 g) by using the paradigm described for experiment 2.
Experiment 6: Expression of POMC and c-Fos with dual-labeled
immunohistochemistry in the paraventricular nucleus (PVN), ARC,
and median eminence (ME). A novel cohort of male rats was given
i3vt injections of apo A-IV (1.5 g/l) (n  5) or saline (n  6). Sixty
minutes after the injection, rats were anesthetized with pentobarbital
(60 mg/kg) and perfused transcardially with 400 ml of 4% parafor-
maldehyde in 0.1 M sodium phosphate buffer (PB) over 15 min.
Brains were removed, postfixed (for 4 h at 4°C), and stored in 20%
sucrose in PB. Brains were sectioned at 40 m with the use of a
microtome at 20°C and stored in cryoprotectant (30% sucrose and
30% ethylene glycol in PB) at 20°C until they were processed for
dual-labeled immunohistochemistry. Available antibodies recogniz-
ing these antigens were all raised in rabbit. To eliminate the possibility
of cross reactivity, a modification of a recently described protocol was
used (15). Free-floating sections were first rinsed in PBS (3  15 min)
and blocked in BSA (0.1%, 1 h). They were then incubated with an
anti-c-Fos antibody (sheep polyclonal, 1:2,000 dilution, Santa Cruz
Biotechnoloy, Santa Cruz, CA) overnight at room temperature in PBS
containing 0.1% BSA and 0.1% Triton X-100. Sections were subse-
quently exposed to biotinylated donkey anti-sheep IgG (1:400 in
incubation solution for 60 min; Jackson Immunoresearch, West
Grove, PA), avidin-biotin-horseradish peroxidase (ABC Elite, 1:1,500
in PBS for 60 min; Vector Laboratories, Burlingame, CA), biotinyl-
ated tyramine (1:250 in PBS containing 3% H2O2 for 10 min; Perkin
Elmer Life Science, Boston, MA), and CY3-conjugated streptavidin
(1:200 in PBS for 30 min; Jackson Immunoresearch). Sections were
then incubated with an anti-POMC antibody (rabbit polyclonal,
1:2,000 dilution; Phoenix Peptides, Belmont, CA) overnight at room
temperature in PBS containing 0.1% BSA and 0.1% Triton X-100 and
in Alexa-488-conjugated donkey anti-rabbit (1:200 for 30 min; Mo-
lecular Probes, Eugene, OR). Developed sections were mounted on
slides and coverslipped with Gelvatol containing an anti-fading agent
(1,4-diazabicyclo[2,2]octane). Immunohistochemical controls in-
cluded omission of primary antibody or preabsorption of diluted
antiserum with nanomolar concentrations of appropriate purified pep-
tides at 4°C for 24 h. In addition, controls included omission of second
primary antibody and application of Alexa 488-conjugated secondary
antibody. Fluorescent-stained sections were examined with a Zeiss
laser-scanning confocal microscope system (Zeiss LSM510). Alexa
488 fluorescence was imaged with a 505-nm emission filter and an
Argon laser (488 nm) and visualized as red signal; CY3 fluorescence
was imaged with a 567-nm emission filter and a HeNe laser (544 nm)
and visualized as green signal. Images were imported into Adobe
Photoshop 6.0 and Microsoft Word to comprise Fig. 7. Images were
not adjusted or altered in any way, except for occasional adjustment
Fig. 1. Effect of third ventricular (i3vt) apolipoprotein (apo) A-IV (0.5, 1.0, or
1.5 g) or saline on 30- and 60-min food intake. *P  0.05 vs. saline and 0.5
g of apo A-IV.
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of brightness. The number of c-Fos-positive cells, as well as POMC
neurons labeled with c-Fos, was scored by observers blind to the
identity of the subjects in approximately the same plane (3 sections
per subject) of the PVN, ARC, and ME in both groups.
Data analysis. Data from each experiment were analyzed with
one-way analysis of variance, followed by the Fisher protected least
squares difference test. A P value  0.05 was considered significant.
All data are expressed as means  SE.
RESULTS
Experiment 1: Determination of a subthreshold dose of apo
A-IV on food intake and body weight. As depicted in Fig. 1, the
i3vt administration of 0.5 g of apo A-IV had no reliable effect
on food intake, whereas the administration of apo A-IV at
doses of 1.0 and 1.5 g significantly reduced food intake
measured at 30 and 60 min compared with saline (P  0.05 in
each case). Apo A-IV at these doses had no effect on 24-h food
intake or body weight (data not depicted), and no adverse
physiological reaction such as sedation or ataxia was observed
after the i3vt infusion of apo A-IV. Thus we concluded that 0.5
g of apo A-IV was subthreshold and that doses of 1.0 and 1.5
g of apo A-IV were above threshold.
Experiment 2: Effect of a subthreshold dose of apo A-IV on
MT-II-elicited suppression of food intake and body weight. As
depicted in Fig. 2, saline  MT-II significantly suppressed
food intake during the first 30 min (1.4  0.2 g), compared
with saline  saline (2.0  0.1 g; P  0.05) and saline  apo
A-IV (1.9  0.2 g; P  0.05). Apo A-IV significantly in-
creased the MT-II-induced suppression of feeding during the
first 30 min (0.9  0.2 vs. 1.4  0.2 g; P  0.05). Although
there was no further enhancement of the reduction of food
intake during the ensuing 30 min, there was also no apparent
compensation in that the intakes of the saline  MT-II and apo
A-IV  MT-II groups remained significantly below those of
their controls.
Experiment 3: Effect of apo A-IV on food intake and body
weight when infused 10 min before a subthreshold dose of
MT-II. Apo A-IV  MT-II decreased food intake significantly
more during the first 30 min than all other treatments (all P 
Fig. 2. Effect of i3vt saline or apo A-IV (0.5 g), in combination with either
saline or metallothionein-II (MT-II; 0.3 nmol), on 30- and 60-min food intake.
*P  0.05 vs. saline and apo A-IV; #P  0.05 vs. MT-II.
Fig. 3. Effect of i3vt saline or apo A-IV (0.5 g), in combination with either
saline or MT-II (0.01 nmol), on 30-min food intake. *P  0.05 vs. each other
group.
Fig. 4. Effect of SHU9119 (0.05, 0.1, or 0.2 nmol) or saline on 30- and 60-min
food intake. *P  0.05 vs. saline.
Fig. 5. Effect of i3vt saline or apo A-IV (1.5 g), in combination with either
saline or SHU9119 (0.1 nmol), on 30-min food intake. *P  0.05 vs. each
other group.
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0.05, Fig. 3). The doses of 0.01 nmol MT-II and 0.5 g apo
A-IV by themselves did not reliably alter 30-min food intake.
There were no significant differences of food intake during the
following 30 min or after 24 h, as well as changes of body
weight after 24 h, for any group.
Experiment 4: Determination of a subthreshold dose of
SHU9119 on food intake and body weight. The i3vt adminis-
tration of 0.05 and 0.1 nmol of SHU9119 had no effect on food
intake, whereas a dose of 0.2 nmol SHU9119 stimulated food
intake significantly during the first 30 min of feeding as well as
during the following 30 min compared with saline (Fig. 4, P 
0.05). Moreover, the dose of 0.2 nmol SHU9119 produced a
significant increase in food intake and body weight over 24 h
(4.1  0.5 vs. 1.0  0.5%, P  0.05). Thus we defined the
subthreshold dose of SHU9119 to elicit food intake as 0.1
nmol.
Experiment 5: Effect of SHU9119 on apo A-IV-elicited
suppression of food intake and body weight. Saline  apo
A-IV (1.5 g) reduced food intake significantly during the first
30 min compared with saline  saline, SHU9119 (0.1 nmol) 
saline, and SHU9119 (0.1 nmol)  apo A-IV (1.5 g) group
(Fig. 5, P  0.05 for each). Hence the subthreshold dose of
SHU9119 completely attenuated the anorectic effect of apo
A-IV over the same time that the SHU9119 by itself had no
effect on feeding. These effects were gone in the following 30
min. There was no significant difference in food intake after
24 h, as well as no change in body weight for 24 h for any
group (data not depicted).
Experiment 6: Expression of POMC and c-Fos with dual-
labeled immunohistochemistry in the PVN, ARC, and ME. The
mean numbers of c-Fos immunoreactive cell neurons in the
PVN, ARC, and ME are depicted in Fig. 6. The group pre-
treated with the central infusion of an anorectic dose of apo
A-IV had significantly more c-Fos-positive neurons than did
saline-treated rats in the PVN (P  0.05). However, there was
no significant difference in the number of c-Fos-positive neu-
rons between apo A-IV-treated rats and control rats in the ARC
or the ME. Moreover, no colocalization of POMC and c-Fos
was observed in the ARC or ME of apo A-IV-treated rats, as
depicted in Fig. 7.
DISCUSSION
These experiments tested the hypothesis that an interaction
occurs between apo A-IV and the melanocortin system with
regard to the control of feeding by the brain. Our data indicate
that there is synergism between apo A-IV and MC3/4-R
signaling that causes anorexia. Moreover, it appears that the
site of this interaction is downstream of the arcuate. It could be
in the PVN, a central site for the integration of signals regu-
lating ingestive behavior, although this cannot be ascertained
from the present data. Thus these findings extend previous
Fig. 6. Effect of i3vt apo A-IV (1.5 g) on the expression of c-Fos in the
paraventricular nucleus (PVN), arcuate nucleus (ARC), and median eminence
(ME). IR, immunoreactive. *P  0.05 vs. saline.
Fig. 7. Representative photomicrographs il-
lustrating dual-labeled immunohistochemis-
try for c-Fos and proopiomelanocortin (POMC)
neurons in the ARC and the ME 60 min after
i3vt administration of apo A-IV (1.5 g). Scale
bar: 50 m.
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work, suggesting a role for apo A-IV in the control of feeding
(9, 10), and lay the groundwork for determining the mechanism
by which this brain-gut peptide acts.
We initially determined that doses of 1.0-g apo A-IV and
higher given i3vt induce a hypophagic response within 30 min,
and that a dose of 0.5 g of apo A-IV does not affect food
intake. These findings are compatible with a previous report
that the i3vt infusion of 1.0 g or higher inhibited food intake
(9). Based on these results, a dose of 0.5-g apo A-IV was
defined as subthreshold and used in subsequent experiments.
We next determined that apo A-IV, in combination with an
anorectic dose of MT-II (0.03 nmol), produced a greater
reduction of 30-min food intake than MT-II alone. These
results indicate that a subthreshold dose of apo A-IV can
potentiate the anorectic effect of MT-II. However, it cannot be
determined from this observation whether there is an additive
or a synergistic interaction, as the MT-II was effective by itself.
We, therefore, repeated the experiment, but used a smaller (i.e.,
subthreshold) dose of MT-II (0.01 nmol). In this instance, the
combination of subthreshold doses of apo A-IV and MT-II
elicited a significant reduction in food intake. The observation
that this dose of MT-II is below the threshold to affect feeding
when administered by itself is consistent with other reports (3,
4, 6). The present results, therefore, indicate that the interaction
of MT-II and apo A-IV meets the criteria for a synergistic
interaction, leading to the reduction in food intake (29). The
data do not reveal how apo A-IV exerts its anorectic action.
Apo A-IV could, for example, interact with neurons that are
activated through MC3/4-R, or it could regulate -MSH re-
lease at the axon level, or it could interact more directly with
MC3/4-R, or it could interact at some point downstream of
melanocortin receptors.
The interaction of apo A-IV with the melanocortin system
suggested that the anorectic effect of apo A-IV may be blocked
by pretreatment with a subthreshold dose of SHU9119. Exper-
iments 4 and 5 assessed this hypothesis. We first determined
that 0.1 nmol (and lower) doses of SHU9119 have no effect on
feeding or body weight over 24 h, an observation consistent
with a previous report (14). This dose of SHU9119, when
administered in combination with apo A-IV, attenuated the
reduction of food intake induced by apo A-IV over 30 min.
SHU9119, when administered i3vt at higher doses, elicits
hyperphagia that lasts several days (12, 13). However, neither
apo A-IV nor SHU9119 alone had any effect on 24-h intake at
the doses used; likewise, neither MT-II nor the combination of
apo A-IV plus MT-II reduced 24-h intake.
All of the behavioral data are, therefore, consistent and
indicate that apo A-IV exerts its anorectic effect by interacting
with signals that stimulate MC3/4-R. One possible mechanism
to explain these data is that apo A-IV stimulates the release of
POMC-derived -MSH originating in the ARC and projecting
to the PVN, as -MSH binds and activates MC3/4-R and as the
PVN expresses MC3/4-R. This possibility would be consistent
with the observation that a subthreshold dose of apo A-IV
increased the MT-II-induced suppression of feeding and that a
subthreshold dose of SHU9119 attenuated the anorectic effect
of apo A-IV. However, the results of the dual-labeled immu-
nohistochemistry do not easily support an effect of apo A-IV to
increase -MSH release, as there was no change of c-Fos
activity in the ARC and no colocalization with POMC. Al-
though it is possible that apo A-IV activates POMC neurons
without stimulating c-Fos, there is no precedent for this in
previous studies of the melanocortin system. It seems more
likely that apo A-IV acts at feeding-related neurons down-
stream of the arcuate, for example in the PVN on neurons that
either express the MC3/4-R or else converge on neurons that
do. MC3/4-R are expressed in a number of hypothalamic sites,
including the PVN (5), such that the precise site of interaction
cannot be determined from the present data. However, the
recent demonstration that apo A-IV mRNA is present in the
ventral hypothalamus, near but ventral to the PVN (17), sug-
gests that an endogenous circuit may exist within the hypo-
thalamus in which apo A-IV contributes to anorexia by inter-
acting with MC3/4-R-containing neurons. In conclusion, the
present experiments indicate that there is a synergistic interac-
tion between the melanocortin system and apo A-IV in the
brain. This interaction causes a short-term reduction of food
intake at some point downstream of POMC neurons.
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